In vitro, AhR has been shown to be an effective target whose inhibition can block the downstream actions of IS and potentially other tryptophan metabolites [13,14] and may provide therapeutic utility in reducing CVD risk in CKD and alleviate its progression. The gene discussed is AHR; the disease is chronic kidney disease.